Zum Inhalt springen
Home » Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu